Cybin Inc
CYBN7.175USD
-0.005-0.07%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
187.28MMarket Cap
LossP/E TTM
More Details of Cybin Inc Company
Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N, N-dimethyltryptamine (DMT) and dDMT programs create a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II.CYB005 is in Preclinical stage. It has an intellectual property portfolio in the psychedelic drug development sector with over 80 patents granted and over 230 patent applications pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands, and Ireland.
Cybin Inc Info
Ticker SymbolCYBN
Company nameCybin Inc
IPO dateJan 05, 2018
CEOSo (Eric How-Lun)
Number of employees50
Security typeOrdinary Share
Fiscal year-endJan 05
Address100 King Street West
CityTORONTO
Stock exchangeNASDAQ OMX – NASDAQ Basic Amex
CountryCanada
Postal codeM5X 1C9
Phone19087648385
Websitehttps://www.cybin.com
Ticker SymbolCYBN
IPO dateJan 05, 2018
CEOSo (Eric How-Lun)
Company Executives of Cybin Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Alex Nivorozhkin
Mr. Alex Nivorozhkin
Chief Scientific Officer
Chief Scientific Officer
5.25M
+5.65%
Mr. Gabriel Fahel
Mr. Gabriel Fahel
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
405.35K
+0.54%
Mr. Eric How-Lun So
Mr. Eric How-Lun So
Executive Chairman of the Board, President, Interim Chief Executive Officer
Executive Chairman of the Board, President, Interim Chief Executive Officer
311.12K
-97.41%
Mr. Paul Glavine
Mr. Paul Glavine
Director, Chief Growth Officer
Director, Chief Growth Officer
299.67K
-97.37%
Ms. Theresa Firestone
Ms. Theresa Firestone
Lead Independent Director
Lead Independent Director
1.06K
-97.37%
Mr. Grant B. Froese
Mr. Grant B. Froese
Independent Director
Independent Director
--
--
Mr. Greg Cavers
Mr. Greg Cavers
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Mark Lawson
Mr. Mark Lawson
Independent Director
Independent Director
--
--
Mr. Aaron Bartlone
Mr. Aaron Bartlone
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Eric Hoskins
Dr. Eric Hoskins
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Alex Nivorozhkin
Mr. Alex Nivorozhkin
Chief Scientific Officer
Chief Scientific Officer
5.25M
+5.65%
Mr. Gabriel Fahel
Mr. Gabriel Fahel
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
405.35K
+0.54%
Mr. Eric How-Lun So
Mr. Eric How-Lun So
Executive Chairman of the Board, President, Interim Chief Executive Officer
Executive Chairman of the Board, President, Interim Chief Executive Officer
311.12K
-97.41%
Mr. Paul Glavine
Mr. Paul Glavine
Director, Chief Growth Officer
Director, Chief Growth Officer
299.67K
-97.37%
Ms. Theresa Firestone
Ms. Theresa Firestone
Lead Independent Director
Lead Independent Director
1.06K
-97.37%
Mr. Grant B. Froese
Mr. Grant B. Froese
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Nivorozhkin (Alex)
10.52%
VR Adviser, LLC
7.70%
Tang Capital Management, LLC
3.67%
Rosalind Advisors, Inc.
3.01%
Tziras (George)
2.60%
Other
72.51%
Shareholders
Shareholders
Proportion
Nivorozhkin (Alex)
10.52%
VR Adviser, LLC
7.70%
Tang Capital Management, LLC
3.67%
Rosalind Advisors, Inc.
3.01%
Tziras (George)
2.60%
Other
72.51%
Shareholder Types
Shareholders
Proportion
Individual Investor
17.51%
Hedge Fund
13.24%
Venture Capital
7.70%
Investment Advisor
4.82%
Research Firm
0.73%
Investment Advisor/Hedge Fund
0.44%
Private Equity
0.31%
Bank and Trust
0.22%
Other
55.04%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
193
13.64M
167.91%
+3.84M
2025Q3
197
11.14M
329.22%
+1.28M
2025Q2
193
9.85M
375.33%
+49.46K
2025Q1
196
9.29M
395.64%
-76.21M
2024Q4
191
8.43M
449.88%
-2.02M
2024Q3
182
9.72M
1675.89%
-283.03M
2024Q2
190
292.76M
44.98%
-25.29M
2024Q1
181
317.25M
8.97%
+249.02M
2023Q4
164
59.62M
8.97%
+31.94M
2023Q3
155
27.56M
6.80%
+20.22M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Nivorozhkin (Alex)
5.25M
20.85%
+280.74K
+5.65%
Mar 31, 2024
Tang Capital Management, LLC
1.83M
7.27%
--
--
Jun 30, 2025
Rosalind Advisors, Inc.
810.92K
3.22%
--
--
Jun 30, 2025
Tziras (George)
1.29M
5.14%
--
--
Jul 24, 2024
Point72 Asset Management, L.P.
1.61M
6.38%
+280.13K
+21.12%
Jun 30, 2025
Deep Track Capital LP
1.53M
6.07%
--
--
Jun 30, 2025
Bartlone (Aaron Frank)
901.07K
4.51%
+200.00K
+28.53%
Jun 28, 2024
Acorn Capital Advisors, LLC
734.39K
2.92%
--
--
Jun 30, 2025
Fahel (Gabriel)
405.35K
1.61%
+2.17K
+0.54%
Sep 02, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
AdvisorShares Psychedelics ETF
6.69%
iShares Biotechnology ETF
0.01%
Simplify Propel Opportunities ETF
0%
AdvisorShares Psychedelics ETF
Proportion6.69%
iShares Biotechnology ETF
Proportion0.01%
Simplify Propel Opportunities ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Aug 28, 2024
Merger
38→1
Aug 28, 2024
Merger
38→1
Aug 28, 2024
Merger
38→1
Aug 28, 2024
Merger
38→1
Date
Type
Ratio
Aug 28, 2024
Merger
38→1
Aug 28, 2024
Merger
38→1
Aug 28, 2024
Merger
38→1
Aug 28, 2024
Merger
38→1
FAQs
Who are the top five shareholders of Cybin Inc?
The top five shareholders of Cybin Inc are:
Nivorozhkin (Alex) holds 5.25M shares, accounting for 20.85% of the total shares.
Tang Capital Management, LLC holds 1.83M shares, accounting for 7.27% of the total shares.
Rosalind Advisors, Inc. holds 810.92K shares, accounting for 3.22% of the total shares.
Tziras (George) holds 1.29M shares, accounting for 5.14% of the total shares.
Point72 Asset Management, L.P. holds 1.61M shares, accounting for 6.38% of the total shares.
Nivorozhkin (Alex) holds 5.25M shares, accounting for 20.85% of the total shares.
Tang Capital Management, LLC holds 1.83M shares, accounting for 7.27% of the total shares.
Rosalind Advisors, Inc. holds 810.92K shares, accounting for 3.22% of the total shares.
Tziras (George) holds 1.29M shares, accounting for 5.14% of the total shares.
Point72 Asset Management, L.P. holds 1.61M shares, accounting for 6.38% of the total shares.
What are the top three shareholder types of Cybin Inc?
The top three shareholder types of Cybin Inc are:
Nivorozhkin (Alex)
VR Adviser, LLC
Tang Capital Management, LLC
Nivorozhkin (Alex)
VR Adviser, LLC
Tang Capital Management, LLC
How many institutions hold shares of Cybin Inc (CYBN)?
As of 2025Q4, 193 institutions hold shares of Cybin Inc, with a combined market value of approximately 13.64M, accounting for 167.91% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -161.31%.
What is the biggest source of revenue for Cybin Inc?
In --, the -- business generated the highest revenue for Cybin Inc, amounting to -- and accounting for --% of total revenue.
